ASMB Profile
Assembly Biosciences, Inc. is a clinical-stage biotechnology firm focused on the discovery and development of innovative therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Based in South San Francisco, California, the company is at the forefront of developing new treatments for HBV, a serious and chronic viral infection that affects millions globally. Assembly Biosciences is dedicated to advancing its pipeline of antiviral therapies through rigorous clinical testing and strategic collaborations.
The company's lead therapeutic candidate, Vebicorvir, has successfully completed Phase 2 clinical trials and is designed to treat patients with chronic HBV infection. Vebicorvir represents a novel approach in the management of HBV, targeting key aspects of the virus’s lifecycle to improve treatment outcomes. In addition to Vebicorvir, Assembly Biosciences is advancing ABI-H3733, which has completed Phase 1a clinical studies, and ABI-4334, currently in pre-clinical trials. These candidates are part of a broader strategy to develop effective and innovative treatments for HBV, addressing various stages and challenges associated with the infection.
Assembly Biosciences has formed strategic collaborations with several key industry players to enhance its research and development efforts. Notable partnerships include agreements with BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc., focusing on evaluating a triple combination treatment for chronic HBV infection. Additionally, the company has entered into licensing agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC, to leverage external expertise and accelerate its therapeutic development.
Founded in 2005 and originally known as Ventrus Biosciences, Inc., Assembly Biosciences rebranded in June 2014 to better reflect its focus on hepatitis B research. The company's commitment to advancing HBV therapies is driven by its innovative research, robust clinical pipeline, and strategic alliances, positioning it as a significant player in the field of antiviral drug development. Assembly Biosciences continues to build on its expertise and partnerships to address unmet medical needs and improve patient outcomes in the global fight against hepatitis B.
|
